

COVID-19 Vaccine Information Brief

May 20, 2022

Changes to the document from the previous version are highlighted in yellow.

The next Vaccine Information Brief will be June 3, 2022

IMPORTANT/NEW COVID-19 Vaccine Information

- COVID-19 Vaccine Allocation and Ordering Cadence for Memorial Day 2022
- ACIP Expand Eligibility for Pfizer-BioNTech COVID-19 Vaccine Booster Dose to Children 5 through 11 Years
- Vaccine Storage and Handling Toolkit Updated
- COVID-19 State of Vaccination Confidence Insights Report
- FDA Limits Use of Janssen COVID-19 Vaccine to Certain Individuals
- Interim Clinical Considerations for Use of COVID-19 Vaccines
- Vaccination Cards and Additional Doses of COVID-19 Vaccine
- Pfizer COVID-19 Vaccine Medical Updates on Current & Immunization Site Training
- Vaccine Expiration Date Resources
- V-Safe After Vaccination Health Checker

COVID-19 Vaccine Allocation and Ordering Cadence for Memorial Day 2022

The Department will continue to survey Local Public Health Agencies (LPHAs) biweekly to determine each county's desired COVID-19 vaccine allocation. Please see the allocation and ordering cadence below for the Memorial Holiday weekend. IDPH will be closed Monday May 30, 2022.

Week of May 30, 2022 - All COVID-19 Vaccines

- IDPH Closed - May 30, 2022
- Allocation Survey Sent - May 31, 2022 - 8:30 am
- Allocation Survey Due Back to IDPH - June 1, 2022 - 12:00 pm
- Allocation Posted in IRIS - June 2, 2022 - 8:30 am
- Allocation Due Back to IDPH in IRIS - June 2, 2022 - 3:00 pm

Healthcare providers may implement the following recommendations from CDC effective immediately.

FDA and ACIP Expand Eligibility for Pfizer-BioNTech COVID-19 Vaccine Booster Dose to Children 5 through 11 Years

On May 17, 2022, the [U.S. Food and Drug Administration](#) amended the emergency use authorization (EUA) for the Pfizer-BioNTech COVID-19 Vaccine, authorizing the use of a single booster dose for administration to

individuals 5 through 11 years of age at least five months after completion of a primary series with the Pfizer-BioNTech COVID-19 Vaccine.

Following the meeting of the Advisory Committee on Immunization Practices' (ACIP), CDC is expanding eligibility of COVID-19 vaccine booster doses to everyone 5 years of age and older. **CDC now recommends children ages 5 through 11 years should receive a booster shot 5 months after their initial Pfizer-BioNTech vaccination series.**

In addition, CDC is strengthening its recommendation that those 12 and older who are immunocompromised and those 50 and older should receive a second booster dose at least 4 months after their first. Over the past month there has been steady increases in cases, with a steep and substantial increase in hospitalizations for older Americans. While older Americans have the highest coverage of any age group of first booster doses, most older Americans received their last dose (either their primary series or their first booster dose) many months ago, leaving many who are vulnerable without the protection they may need to prevent severe disease, hospitalization, and death.

Booster Dose Recommendations

| Age | Pfizer-BioNTech COVID-19 vaccine primary series | Moderna COVID-19 vaccine primary series | Janssen COVID-19 vaccine primary series |
|-------------------|---|---|---|
| ≥18 years | Should receive a booster <u>5 months</u> after receipt of primary series dose | Should receive a booster <u>5 months</u> after receipt of primary series dose | Should receive a booster <u>2 months</u> after receipt of primary series dose |
| 5–17 years | Should receive a booster <u>5 months</u> after receipt of primary series dose | Not authorized | Not authorized |

Refer to [CDC's Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States](#) for guidance on populations eligible for additional boosters.

FDA Evaluation of Safety

The safety of a single booster dose of the Pfizer-BioNTech COVID-19 Vaccine in this age group was assessed in approximately 400 children who received a booster dose at least five months (range 5 to 9 months) after completing a two-dose primary series. The most commonly reported side effects were pain, redness and swelling at the injection site, as well as fatigue, headache, muscle or joint pain and chills and fever.

During Omicron predominant period, COVID-19 incidence rates among unvaccinated children ages 5 – 11 years were **1.3X** higher than rates in children vaccinated with a primary series.

Resources

- [Pfizer-BioNTech COVID-19 Vaccine](#)
- [COVID-19 Vaccines](#)
- [Emergency Use Authorization for Vaccines Explained](#)
- [CDC’s Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States \(To be updated early next week\)](#)
- [AMA CPT Codes](#)
 - [COVID-19 CPT Vaccine and Immunization Codes](#)
 - [Category I Vaccine Product Codes](#)

Vaccine Storage and Handling Toolkit Updated

The [Vaccine Storage and Handling Toolkit](#) has been updated with a COVID-19 Vaccine Addendum with information on Storage and Handling best practices for COVID-19 vaccines. All vaccination providers participating in the COVID-19 Vaccination Program must store and handle COVID-19 vaccines under proper conditions to maintain the cold chain as outlined in the toolkit and addendum.

COVID-19 State of Vaccination Confidence Insights Report #25

The [COVID-19 State of Vaccine Confidence Insights Report](#) emphasizes major themes influencing COVID-19 vaccine hesitancy and uptake, categorized by the level and type of threat to vaccine confidence, degree of spread, and directionality. By examining how Americans think and feel, social processes, and the practical issues around vaccination, the Insights Report seeks to identify emerging issues of misinformation, disinformation, and places where intervention efforts can positively impact vaccine confidence across the United States. Previous reports can be found at the following link: [COVID-19 State of Vaccine Confidence Insights Reports](#).

Get Email Updates

Receive email updates about this page.

[What's this?](#)

[Get Email Updates](#)

Interim Clinical Considerations for Use of COVID-19 Vaccines

CDC continually updates its guidance for COVID-19 vaccination. To view all updates, please visit [CDC’s Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States](#).

Healthcare providers can sign up to receive email notification when the Interim Clinical Considerations are updated. The link to sign up is located on the right side of the Interim Clinical Considerations page.

Vaccination Cards and Additional Doses of COVID-19 Vaccine

If there is no space on a vaccine card to document additional or repeated doses of COVID-19 vaccine, please document new vaccinations on a NEW card and staple all patient vaccine cards together. This will ensure the patient has all of their vaccine records maintained in a single location.

Pfizer COVID-19 Vaccine Medical Updates on Current & Immunization Site Training

At this time, the Medical Affairs team is continuing to educate providers on Purple, Gray, and Orange caps as well as medical updates. To access dates and links for upcoming training sessions, please visit:

<https://www.pfizermedicalinformation.com/en-us/medical-updates>.

Vaccine Expiration Date Resources

Always be sure to check the manufacturer's website to obtain the most up-to-date expiration dates for COVID-19 vaccines. It is important for healthcare providers to update vaccine expiration dates in IRIS. Questions regarding IRIS vaccine inventory and adjusting expiration dates can be directed to the IRIS Helpdesk at 800-374-3958.

For EUA COVID-19 vaccines that do not have a final expiration date, the CDC has set an expiration date of 12/31/2069 to serve as a *placeholder date*. Such vaccines have a dynamic expiration date, which can change over time as additional stability data become available. This placeholder date, which is far in the future, is intended to serve as a prompt for the provider to check the latest expiry information on the manufacturer's website. **It is important for healthcare providers to update vaccine expiration dates in IRIS.**

The Pfizer COVID-19 vaccine:


It is important for all healthcare providers to double check all shelf life extensions for all Pfizer products.

Pfizer does not have an expiration date look up tool for these vaccines. **The date on the label is NOT the expiration date for the GRAY and ORANGE cap vials, instead, each vial has the lot number and date of manufacture printed on the label.** Pfizer does provide guidance for expiration dates on their [website](#).

- *Regardless of storage condition, **GRAY CAP** and **ORANGE CAP** vaccine vials should not be used after 12 months from the **date of manufacture** printed on the vial and cartons.
- †The **PURPLE CAP** vaccine vials should not be used past the 12-month expiry. For vials with expiry dates of October 2021 through March 2022, the printed date on the label/carton reflects 6-month expiry. For vials with expiry dates of July 2022 through November 2022, the printed date on the label/carton reflects 9-month expiry. The vaccine should not be used past the 12-month (updated) expiry date in the table below.


Resources for Pfizer COVID-19 vaccine:

- [FDA COVID-19 Vaccine Page \(Page will be updated with latest EUA changes\)](#)
- [EUA Fact Sheet for Vaccination Providers \(12 years of age and older\), DILUTE BEFORE USE, Purple Cap](#)
- [EUA Fact Sheet for Vaccination Providers \(12 years of age and older\), DO NOT DILUTE, Gray Cap](#)
- [EUA Fact Sheet for Vaccination Providers \(5-11 years of age\), DILUTE BEFORE USE, Orange Cap](#)



Expiry information for Ages 5 through 11
DILUTE BEFORE USE Orange Cap presentation*
and Ages 12 years and older DO NOT DILUTE
Gray Cap presentation*

| Printed Manufacturing Date | 12-Month Expiry Date |
|----------------------------|----------------------|
| 06/2021 | 31-May-2022 |
| 07/2021 | 30-Jun-2022 |
| 08/2021 | 31-Jul-2022 |
| 09/2021 | 31-Aug-2022 |
| 10/2021 | 30-Sep-2022 |
| 11/2021 | 31-Oct-2022 |
| 12/2021 | 30-Nov-2022 |
| 01/2022 | 31-Dec-2022 |
| 02/2022 | 31-Jan-2023 |
| 03/2022 | 28-Feb-2023 |



Expiry information for Ages 12 years and older
DILUTE BEFORE USE Purple Cap presentation'

| Printed Expiry Date | Updated Expiry Date |
|---------------------|---------------------|
| 10/2021 | 30-Apr-2022 |
| 11/2021 | 31-May-2022 |
| 12/2021 | 30-Jun-2022 |
| 01/2022 | 31-Jul-2022 |
| 02/2022 | 31-Aug-2022 |
| 03/2022 | 30-Sept-2022 |
| 07/2022 | 31-Oct-2022 |
| 08/2022 | 30-Nov-2022 |
| 09/2022 | 31-Dec-2022 |
| 10/2022 | 31-Jan-2023 |
| 11/2022 | 28-Feb-2023 |

Janssen COVID-19 vaccine: The expiration date is NOT printed on the vaccine vial or carton. To determine the expiration date:

- Scan the QR code located on the outer carton, or
- Call 1-800-565-4008, or
- Go to www.vaxcheck.jnj/

Moderna COVID-19 vaccine:

The expiration date is NOT printed on the vaccine vial or carton. To determine the expiration date:

- Scan the QR code located on the outer carton, or
- Go to www.modernatx.com/covid19vaccine-eua/

CDC’s [COVID-19 Vaccine Expiration Date Tracking Tool](#) can help providers keep track of the expiration date by lot number.

COVID-19 Vaccine Administration Dashboard

Reporting of vaccination data to the [COVID-19 Vaccine Administration Dashboard](#) and DOMO will transition to monthly as of May 3, 2022. Additional data outside of these monthly timeframes will not be available.

V-safe After Vaccination Health Checker

V-safe is a smartphone-based tool that uses text messaging and web surveys to provide personalized health check-ins after an individual receives a COVID-19 vaccination. V-safe web pages feature information on how to register and complete a v-safe health check-in (including step-by-instructions with images), troubleshooting, FAQs, and contact information for technical support. These web pages will be continuously updated with additional resources.

- V-safe information sheet and poster: posted on the vaccine webpage and available in 5 languages: English, Spanish, Korean, Vietnamese, and Simplified Chinese
- [V-safe after vaccination health checker website](#)
- [V-safe Print Resources](#)
- [V-safe Poster-11x17](#)
- [Vaccine Adverse Event Reporting System \(VAERS\)](#)